Combination of Type I and II tyrosine kinase inhibitors—avapritinib and sunitinib—in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report

BACKGROUND: Tyrosine kinase inhibitors (TKIs) are currently the main treatment choice for gastrointestinal stromal tumors (GISTs). However, the long-term use of TKIs can lead to drug resistance. There is no study or clinical report of combination therapies of TKIs that have been approved for marketi...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaodan, Huang, Shaoqing, Shi, Yihang, Guan, Zhaoming, Chen, Sile, Feng, Yun, Xia, Yanzhe, Zhang, Xinhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577760/
https://www.ncbi.nlm.nih.gov/pubmed/36267752
http://dx.doi.org/10.21037/atm-22-3746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577760/
https://www.ncbi.nlm.nih.gov/pubmed/36267752
http://dx.doi.org/10.21037/atm-22-3746

Ejemplares similares